NuView Life Sciences is creating binary cancer diagnostics and Theranostics to improve patient outcomes and reducing healthcare costs.
NuView Life Sciences
Binary cancer diagnostics and theranostics,
improving patient outcomes and reducing healthcare costs.
NuView Life Sciences is working to improve the way cancer is diagnosed and treated for our modern healthcare system.
Led by a multi-disciplinary team of industry experts with decades of combined experience in healthcare and medical imaging technologies, NuView Life Sciences is poised to change how we look for and respond to cancer.
NuView Life Sciences has a strong mission – to change the way many types of cancer are diagnosed and treated using precision medicine technology. Diagnosing and treating cancer with a targeted, specific approach to the disease will help to increase positive patient outcomes while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers.
NuView Life Sciences’s leading technology, NV-VPAC1TM consists of a series of peptide analogs that target the vasoactive intestinal peptide receptor type 1 (VPAC1). The VPAC1 receptor becomes overexpressed in certain key malignancies including breast, prostate, colon, bladder, and endometrial cancer.
Would you like to read more?
Get Answers From the National Cancer Institute
Information specialists at NCI’s Cancer Information Service (CIS), NCI’s contact center, are available to help answer your cancer-related questions whether you are a patient, family member or friend, health care provider, or researcher. The service is available in English and Spanish.